Literature DB >> 29707302

Prognostic and clinicopathological significance of platelet to lymphocyte ratio in esophageal cancer: a meta-analysis.

Juhong Deng1, Peng Zhang2, Yue Sun2, Ping Peng2, Yu Huang2.   

Abstract

BACKGROUND: The prognostic and clinicopathological significance of the platelet to lymphocyte ratio (PLR) has been studied in various cancers. However, studies examining the role of PLR in esophageal cancer have not yielded consistent results. The purpose of this meta-analysis was to study the prognostic and clinicopathological significance of PLR in esophageal cancer patients.
METHODS: We performed a literature search in three major databases: PubMed, Web of Science and Embase (up until May 1, 2017). The clinicopathologic significance of PLR and its prognostic significance were analyzed.
RESULTS: Our meta-analysis consisted of 13 studies with 4,621 patients. The pooled hazard ratios (HRs) showed that a high PLR was associated with poor survival of esophageal cancer [HR =1.283; 95% confidence interval (CI): 1.173-1.404; P<0.001]. Subgroup analysis revealed that elevated PLR was associated with poor survival in esophageal squamous cell carcinoma (HR =1.281; 95% CI: 1.098-1.493; P=0.002). The pooled odds ratio (OR) indicated that high PLR was also associated with the depth of tumor invasion (OR =1.543, 95% CI: 1.269-1.876, P<0.001), lymph node metastasis (OR =1.427, 95% CI: 1.195-1.705, P<0.001), tumor length (OR =1.81, 95% CI: 1.331-2.461, P<0.001), and Tumor stage (OR =1.459, 95% CI: 1.235-1.724, P<0.001).
CONCLUSIONS: Our results demonstrate that elevated PLR was significantly associated with poor prognosis of esophageal cancer. Furthermore, the high PLR might predict worse clinicopathological features of esophageal cancer patients.

Entities:  

Keywords:  Meta-analysis; esophageal neoplasms; platelet to lymphocyte ratio (PLR); prognosis

Year:  2018        PMID: 29707302      PMCID: PMC5906230          DOI: 10.21037/jtd.2018.02.58

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  37 in total

Review 1.  Platelet-targeted pharmacologic treatments as anti-cancer therapy.

Authors:  P Gresele; S Momi; M Malvestiti; M Sebastiano
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

2.  Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer.

Authors:  Naohiro Kobayashi; Shingo Usui; Shinji Kikuchi; Yukinobu Goto; Mitsuaki Sakai; Masataka Onizuka; Yukio Sato
Journal:  Lung Cancer       Date:  2011-07-20       Impact factor: 5.705

3.  Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.

Authors:  M Messager; K Neofytou; M A Chaudry; W H Allum
Journal:  Eur J Surg Oncol       Date:  2015-06-30       Impact factor: 4.424

4.  High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Authors:  Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke
Journal:  Clin Cancer Res       Date:  2010-10-18       Impact factor: 12.531

Review 5.  Cancer-related inflammation.

Authors:  Juliana Candido; Thorsten Hagemann
Journal:  J Clin Immunol       Date:  2012-12-09       Impact factor: 8.317

Review 6.  Inflammation and cancer: advances and new agents.

Authors:  Shanthini M Crusz; Frances R Balkwill
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

7.  Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma.

Authors:  Peng Liu; Yuan Zhu; Luying Liu
Journal:  Onco Targets Ther       Date:  2015-06-04       Impact factor: 4.147

Review 8.  The tumor microenvironment in esophageal cancer.

Authors:  E W Lin; T A Karakasheva; P D Hicks; A J Bass; A K Rustgi
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

9.  Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer.

Authors:  Xiaobin Gu; Xian-Shu Gao; Ming Cui; Mu Xie; Chuan Peng; Yun Bai; Wei Guo; Linjun Han; Xiaodong Gu; Wei Xiong
Journal:  Oncotarget       Date:  2016-08-02

10.  The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China.

Authors:  Peng Sun; Fei Zhang; Cui Chen; Xiwen Bi; Hang Yang; Xin An; Fenghua Wang; Wenqi Jiang
Journal:  Oncotarget       Date:  2016-07-05
View more
  10 in total

1.  Platelet-to-Lymphocyte Ratio Multiplied by the Cytokeratin-19 Fragment Level as a Predictor of Pathological Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.

Authors:  Yuji Shishido; Tomoyuki Matsunaga; Shohei Sawata; Masahiro Makinoya; Wataru Miyauchi; Kozo Miyatani; Chihiro Uejima; Masaki Morimoto; Yuki Murakami; Takehiko Hanaki; Kyoichi Kihara; Manabu Yamamoto; Naruo Tokuyasu; Shuichi Takano; Teruhisa Sakamoto; Hiroaki Saito; Toshimichi Hasegawa; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2021-08-24       Impact factor: 1.641

2.  Platelets-to-lymphocyte ratio and esophageal cancer.

Authors:  Antonios Athanasiou; Michael Spartalis; Eleftherios Spartalis
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component.

Authors:  Ziyu Zhu; Jialiang Gao; Zhixin Liu; Chunfeng Li; Yingwei Xue
Journal:  Biomed Res Int       Date:  2021-05-03       Impact factor: 3.411

4.  Predictive value of postoperative C-reactive protein-to-albumin ratio in anastomotic leakage after esophagectomy.

Authors:  Chi Zhang; Xiao Kun Li; Li Wen Hu; Chao Zheng; Zhuang Zhuang Cong; Yang Xu; Jing Luo; Gao Ming Wang; Wen Feng Gu; Kai Xie; Chao Luo; Yi Shen
Journal:  J Cardiothorac Surg       Date:  2021-05-17       Impact factor: 1.637

5.  Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.

Authors:  Ji Feng Feng; Liang Wang; Qi-Xun Chen; Xun Yang
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

6.  Prognostic Value of Combined Analysis of CTLA-4 and PLR in Esophageal Squamous Cell Carcinoma (ESCC) Patients.

Authors:  Cui-Ying Zhang; Juan Zhang; Yun-Fan Ma; Hong Zhe; Ren Zhao; Yan-Yang Wang
Journal:  Dis Markers       Date:  2019-08-14       Impact factor: 3.434

7.  Prognostic impact of platelet-to-lymphocyte ratio on diffuse large B-cell lymphoma: a meta-analysis.

Authors:  Ying Chen; Zongxin Zhang; Qiu Fang; Huiqin Jian
Journal:  Cancer Cell Int       Date:  2019-09-24       Impact factor: 5.722

8.  The clinical significance of preoperative serum fibrinogen levels and platelet counts in patients with gallbladder carcinoma.

Authors:  Peng Cao; Lei Jiang; Liang-Yi Zhou; Yan-Ling Chen
Journal:  BMC Gastroenterol       Date:  2021-10-07       Impact factor: 3.067

9.  The development of a nomogram and the prognostic prediction value of patients with esophageal squamous cell carcinoma undergoing radical radiotherapy.

Authors:  Ling Xiao; Jiahua Lyu; Meihua Chen; Liu Wang; Jing Huang; Yajun Wei; Tao Li
Journal:  Future Sci OA       Date:  2022-01-24

10.  Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer.

Authors:  Tiago Cruz Tomás; Inês Eiriz; Marina Vitorino; Rodrigo Vicente; João Gramaça; Alicia Guadalupe Oliveira; Paulo Luz; Mafalda Baleiras; Ana Sofia Spencer; Luísa Leal Costa; Patrícia Liu; Joana Mendonça; Magno Dinis; Teresa Padrão; Marisol Correia; Gonçalo Atalaia; Michelle Silva; Teresa Fiúza
Journal:  World J Gastrointest Oncol       Date:  2022-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.